Back to Clinical Trials

Brief Title: Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer


  • Org Study ID: 20-410
  • Secondary ID: N/A
  • NCT ID: NCT04670445
  • Sponsor: Massachusetts General Hospital


The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer.

The intervention is an educational video and question prompt list (QPL) to promote communication between patients, caregivers, and the oncology team about the risks and benefits of immunotherapy.


This two-part study will 1) refine and 2) pilot test an intervention to improve participant's and caregiver knowledge and increase communication with the oncology team about immunotherapy.

* The intervention involves watching a video developed to educate patients regarding the risks, benefits, and potential outcomes of immunotherapy treatment and reviewing an immunotherapy-focused QPL prior to ICI initiation.
* In Part 1 of this study, investigators will conduct a small open pilot to refine the intervention and study procedures.
* In Part 2, investigators will conduct a single-site pilot randomized controlled trial including 130 patients and their caregivers, to evaluate the feasibility of intervention delivery, and the preliminary efficacy of the intervention in improving patient and caregiver knowledge.

  • Overall Status
    Active, not recruiting
  • Start Date
    January 23, 2021
  • Phase
    Not Applicable
  • Study Type


Primary Outcome 1 - Measure:

Primary Outcome 1 - Timeframe: N/A


  • Stage IV Melanoma
  • Advanced Lung Cancer
  • Stage IV Non-Small Cell Lung Cancer
  • Unresectable Non-Small Cell Lung Carcinoma
  • Unresectable Stage III Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer Extensive Stage
  • Stage IV Merkel Cell Carcinoma
  • Stage IV Cutaneous Squamous Cell Carcinoma
  • Stage IV Basal Cell Carcinoma
  • Stage IV Breast Cancer
  • Stage IV Colorectal Cancer
  • Stage IV Gastric Cancer
  • Stage IV Esophageal Cancer
  • Stage IV Hepatocellular Cancer
  • Stage IV Renal Cell Carcinoma
  • Stage IV Bladder Cancer
  • Stage IV Head and Neck Squamous Cell Carcinoma
  • Stage IV Cervical Cancer
  • Stage IV Endometrial Cancer
  • Stage IV Mesothelioma
  • Immunotherapy
  • Immune Checkpoint Inhibitors


Inclusion Criteria:
* All participants (Patients and Caregivers)-Table 1
* Age 18 or older

- * Ability to read and respond in English

- * Patient Inclusion Criteria (in addition to Table 1)
* Receiving care in the MGH Cancer Center

- * Diagnosis of advanced (stage IV) melanoma or advanced, incurable lung cancer, including stage IV non-small cell lung cancer (NSCLC), unresectable stage III NSCLC, extensive-stage small cell lung cancer.

- * Plan to initiate immunotherapy with an ICI (pembrolizumab, nivolumab, ipilimumab, atezolizumab or combination), per clinician documentation in the electronic health record or study staff communication with clinician

- * Caregiver Inclusion Criteria (in addition to Table 1)
* Identified as "a supportive person involved in their cancer care" by a patient enrolled in the study
Exclusion criteria
* Major psychiatric condition or comorbid illness that prohibits participation in the study

- * Cognitive impairment that prohibits provision of informed consent or participation in the study

- * Pregnant women

- * Prisoners

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No


Name: Laura A Petrillo, MD

Role: Principal Investigator

Affiliation: Massachusetts General Hospital

Overall Contact

Name: N/A

Phone: N/A

Email: N/A


Facility Status Contact